Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,696.01 24.75 0.11%

Codexis Appoints John J. Nicols as President and Chief Executive Officer



  Codexis Appoints John J. Nicols as President and Chief Executive Officer

Business Wire

REDWOOD CITY, Calif. -- June 04, 2012

Codexis, Inc. (NASDAQ:CDXS), a developer of industrial enzymes to enable the
cost-advantaged production of biofuels, bio-based chemicals and pharmaceutical
intermediates, today announced the appointment of John J. Nicols as President
and Chief Executive Officer. Mr. Nicols will begin his new role on June 13,
2012. Mr. Nicols will be appointed to the company's Board of Directors
following the commencement of his employment as President and Chief Executive
Officer.

Mr. Nicols served most recently as Senior Vice President, Strategic
Development and Catalysts, at Albemarle Corporation (NYSE: ALB), a specialty
chemicals company with a current market capitalization in excess of $5
billion. As head of the largest of Albemarle’s three publicly reported
business segments, Mr. Nicols has been responsible for a $1.1 billion P&L
statement covering a diverse set of global catalyst business operations and
joint ventures. Since Mr. Nicols took over the Catalysts division in January
2007, sales have grown $278 million, which equates to a compound annual growth
rate of 5.9%. In addition, the Catalysts division has generated segment income
margins of at least 28 percent over the last two years, which are nearly
double the margins of earlier periods. The resulting Catalysts division
segment income grew by $200 million from 2006 to 2011, a compound annual
growth rate of 21.2%. In addition to his financial achievements in Catalysts,
Mr. Nicols strategically drove Albemarle to expand globally, including
substantial new facilities investment projects currently underway in South
Korea, Saudi Arabia and Brazil. The projects in Saudi Arabia and Brazil are
joint ventures with leading global companies, SABIC and Petrobras,
respectively.

During his more than 20-year career at Albemarle, Mr. Nicols managed multiple
divisions of the company, driving sustained growth in its Flame Retardants and
Fine Chemistry business units, and completed a three-year assignment in Tokyo,
Japan from 1995 to 1998. He also co-led a corporate strategy review that
focused on driving the corporation’s organic new business development
opportunities. The success of this project recently led Albemarle to appoint
Mr. Nicols as head of company-wide Strategic Development.

“John Nicols brings to Codexis a 20-year track record of success in
commercializing new products in the chemicals industry, managing growth for
multiple business units, and developing and executing corporate strategy,”
said Tom Baruch, Chairman of the Board for Codexis, Inc. “John has the perfect
mix of leadership and experience to bring Codexis CodeXyme™ cellulase enzymes
and CodeXol™ detergent alcohol to market.”

“I am excited to become a member of the great team at Codexis, and to lead the
company’s transformation to a world-scale commercial entity in its biofuels
and bio-based chemical businesses. Our first priority is to complete the
development of CodeXyme™ cellulase enzymes and CodeXol™ detergent alcohol,”
said incoming President and CEO, John J. Nicols. “I envision that Codexis’
CodeEvolver™ directed evolution technology platform will continue to generate
differentiated commercial products in the pharmaceuticals, chemicals and fuels
markets.”

“We are all grateful to Peter Strumph for actively leading Codexis during the
last several months. His understanding of the company and his engagement with
our shareholders and employees kept us on course,” Mr. Baruch stated. “With
John’s appointment, the Board and John will now focus on the successful
completion of our pending CFO search.”

Biographical Information for John J. Nicols

Mr. Nicols has served in various capacities at Albemarle Corporation, a public
company focused on the development, manufacture, and marketing of highly
engineered specialty chemicals, since he joined that company in 1990. Since
March 2012, Mr. Nicols has served as its Senior Vice President, Strategic
Development and Catalysts. Mr. Nicols previously served as its Vice President,
Catalysts from January 2007 to February 2012, its Vice President, Fine
Chemistry from June 2002 to December 2006, its Division Vice President, Global
Flame Retardants business from February 1999 through June 2002 and its Asia
Pacific Business Director for the Bromine Chemicals business, based in Tokyo,
Japan, from 1995 to 1998. Prior to his time with Albemarle Corporation, Mr.
Nicols worked for three years in manufacturing and research and development
for Hercules, Inc. Mr. Nicols received a B.S. in Chemical Engineering from the
Polytechnic Institute of New York University and an M.B.A. from the Sloan
School of Management at the Massachusetts Institute of Technology.

About Codexis, Inc.

Codexis, Inc. is a developer of industrial enzymes to enable the
cost-advantaged production of biofuels, bio-based chemicals and pharmaceutical
intermediates. Codexis' product lines include CodeXyme™ Cellulase Enzymes and
CodeXol™ Detergent Alcohol. Partners and customers include global leaders such
as Shell, Merck and Pfizer. For more information, see www.codexis.com.

Forward-Looking Statements

This press release contains forward-looking statements relating to Codexis’
transformation from the development stage to commercialization in its biofuels
and bio-based chemical business opportunities. You should not place undue
reliance on these forward-looking statements because they involve known and
unknown risks, uncertainties and other factors that are, in some cases, beyond
our control and could materially affect actual results. Factors that could
materially affect actual results include our need for substantial additional
capital in the future in order to expand our business, our dependence on our
collaborators and various challenges to the feasability of the production and
commercialization of biofuels and bio-based chemicals derived from cellulose.
Additional factors that could materially affect actual results can be found in
Codexis’ Quarterly Report on Form 10-Q for the period ended March 31, 2012
filed with the Securities and Exchange Commission on May 10, 2012, including
under the caption “Risk Factors.” Codexis expressly disclaims any intent or
obligation to update these forward-looking statements, except as required by
law.

Contact:

Codexis, Inc.
Investors:
Jay Sarwar, 650-421-8126
ir@codexis.com
Media:
Wes Bolsen, 650-421-2356
media@codexis.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement